Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ihab Doss

Interventional Pain Medicine Warrensburg, MO Medical Doctor

NPI 1124006085 CMS profile 4946

407 Burkarth Road, Suite 301, Warrensburg, MO 64093

Open in the dashboard

General payments

$6,477

52 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ihab Doss of Warrensburg, MO is reported in the CMS Open Payments database as having received $6,477 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,099 8
2024 General $96 4
2023 General $911 6
2022 General $1,022 8
2021 General $343 6
2020 General $151 2
2019 General $2,855 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ihab Doss
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ihab Doss were reported at $1,099. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ihab Doss Interventional Pain Medicine median Middle half National median
2019 $2,855 $684 $216–$2,079 $163
2020 $151 $382 $122–$1,109 $114
2021 $343 $552 $167–$1,554 $132
2022 $1,022 $605 $187–$1,924 $149
2023 $911 $671 $195–$1,915 $160
2024 $96 $684 $206–$1,837 $164
2025 $1,099 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,516 23 payments
  2. Vertiflex, Inc. $2,248 10 payments
  3. Medtronic, Inc. $221 3 payments
  4. Medtronic USA, Inc. $178 3 payments
  5. Spinal Simplicity, LLC $96 2 payments
  6. SPR Therapeutics, Inc $94 5 payments
  7. Boston Scientific Corporation $50 2 payments
  8. Merck Sharp & Dohme Corporation $22 1 payment
  9. Abbott Laboratories $18 1 payment
  10. Saluda Medical Americas, Inc. $18 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,845 16 payments
  2. Food and Beverage $1,631 36 payments
Products named General payments · program years 2019–2025
  1. Superion ISS $2,248 10 payments
  2. SPINEJACK Interventional Spine $1,854 9 payments
  3. MILD DEVICE KIT $1,081 7 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $291 3 payments
  5. INTELLIS $166 1 payment
  6. IVS - AUTOPLEX SYSTEM $138 2 payments
  7. RESTORE $132 1 payment
  8. SPINEJACK Spine $123 1 payment
  9. HA MINUTEMAN G3-R $96 2 payments
  10. SPRINT PNS System $94 5 payments
  11. Other $214 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,318

Median for Pain Management: 951

Drug cost

$11,823

Median for Pain Management: $26,034

Branded share of claims

4.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tizanidine Hcl Generic 449 $5,043
Gabapentin Generic 410 $3,324
Duloxetine Hcl Generic 83 $1,914
Tramadol Hcl Generic 218 $672
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $429
Cyclobenzaprine Hcl Generic 28 $197
Methylprednisolone Generic 12 $108
Meloxicam Generic 49 $72
Amitriptyline Hcl Generic 13 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$150,085

Medicare's payments for the services billed

Medicare patients

330

Average age 74

Services billed

1,816

192 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 34%
Diabetes 33%
Ischemic heart disease 26%
Osteoporosis 24%
Chronic kidney disease 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record